Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:38:42.830Z.
Calculation as of: 2026-10-06T21:38:42.830Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 935c0e980908f1d3c2a070cdd724954857d1623c0e1dbdb6f9240be4a5331b99
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Translational Development Acquisition Corp.
Market Cap
$266.50M
Price/FCF Ratio
N/A
Market Cap
$264.38M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Translational Development Acquisition Corp. (TDAC) | $266.50M | N/A |
| Thunder Bridge Capital Partners V L (TBCVU)vs › | $266.29M | N/A |
| Hawthorn Bancshares, Inc. (HWBK)vs › | $265.95M | N/A |
| Kingstone Companies, Inc. (KINS)vs › | $267.82M | N/A |
| LCNB Corp. (LCNB)vs › | $268.25M | N/A |
| Oaktree Acquisition Corp. II (OACC)vs › | $264.51M | N/A |
| ProCap Acquisition Corp (PCAP)vs › | $264.47M | N/A |
| Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)vs › | $264.38M | N/A |
| Soren Acquisition Corp. (SORN)vs › | $263.53M | N/A |
| Cartesian Growth Corp. Iv (CGCF)vs › | $270.05M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
